# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Clara Barton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI024-SYN
- Date: 2026-06-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Five-month depression review in continuation treatment. **S**

## History of present illness

Ms. Barton returns two months after her twelve-week review. The care manager's telephone PHQ-9 planned for about four weeks after that review was not completed: two calls in May went unanswered while she was at a week-long training course, and no further call was booked. She feels like herself again, with steady energy, and sleeps about seven hours. She has finished fifteen of sixteen CBT sessions and has joined the monthly peer support group. She works about 45 hours a week, walks most days, and sees friends weekly. She takes sertraline 100 mg every morning, has missed no doses, and has no side effects. She has had no suicidal thoughts. **S**

| Element | Detail |
|---|---|
| Interval change | Feels like herself; steady energy |
| Missed contact | Telephone PHQ-9 planned in May not completed |
| Sleep | About seven hours |
| Psychotherapy | Fifteen of sixteen CBT sessions; monthly peer support group |
| Safety | No suicidal thoughts |
| PHQ-9 | 4 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy normal; weight back to her usual |
| Gastrointestinal | Negative | No nausea or bleeding |
| Psychiatric | Negative | Mood good; no suicidal thoughts, elevated mood, or racing thoughts |

3 systems reviewed. **S**

## Current medications

- Sertraline 100 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/74 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 51.6 kg; BMI 22.3 kg/m². All vital signs are synthetic.

PHQ-9: 4. All results are synthetic.

## Change since baseline

- PHQ-9: 18 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, brisk, and cheerful |
| Mental status | Alert; mood "like myself"; affect full and reactive; thought process linear; no suicidal ideation; insight and judgment good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent, in remission** (F33.1). PHQ-9 4: remission, about five months after starting treatment. Because this is at least her second episode, the risk of recurrence is high. Suicide risk remains low. **S**
   - Continue sertraline 100 mg for at least twelve months after remission, then decide together about tapering or longer maintenance.
   - PHQ-9 every two to three months in continuation, with the care-manager registry flagging any missed call.
   - Finish the CBT course and keep the peer support group; agree early warning signs with her therapist.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
2. **Occupational burnout** (Z73.0). Recovered; keeping within the 45-hour limit. **S**
   - No field deployment before the spring; plan any return with her board and review here before and after.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 4: remission |
| Survey | Monthly PHQ-9 between the twelve-week review and today | At least monthly during acute treatment | Deferred | Not done, a deviation from the protocol: the care-manager telephone PHQ-9 planned for about four weeks after the twelve-week review was not completed after two unanswered calls, leaving nine weeks unmeasured. No harm resulted judging by today's review: she reached remission and had no suicidal thoughts. Corrective action: the registry now books a callback within a week after any unanswered call and alerts Dr. Whitcombe if a scheduled score is missing |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors stronger than at intake. Safety plan reviewed |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no side effects |
| Self-management | Psychotherapy, sleep, work hours, and social contact | Every visit during active treatment | Completed today | Fifteen of sixteen CBT sessions; sleep about seven hours; 45-hour week; monthly peer support group |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |

## Goal progress

- Response (PHQ-9 down by at least 50 percent) by twelve weeks. Outcome by 2026-04-14: PHQ-9 7 at twelve weeks, down 61 percent from 18. **S**
- Remission (PHQ-9 below 5) and continuation treatment for at least twelve months after remission. Outcome by 2026-06-16: Remission reached at five months (PHQ-9 4); continuation treatment under way. **S**
- Sleep at least six hours most nights. Outcome by 2026-04-14: About six and a half hours most nights by twelve weeks. **S**
- Phased return to work at no more than 45 hours a week, with no field deployment for at least six months. Outcome by 2026-06-16: Full duties at 45 hours a week from April; no deployment. **S**
- Time with friends or her faith community at least twice a week. Outcome by 2026-06-16: Weekly dinner with friends and weekly services. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- PHQ-9 in two to three months; preventive visit in October. **S**
- Next scheduled visit 2026-10-13: periodic adult preventive visit. **S**
